FCGRT: A Protein Targeted for Small Molecule Inhibitors (G2217)

Target Name: FCGRT

NCBI ID: G2217

FCGRT

FCGRT: A Protein Targeted for Small Molecule Inhibitors

FCGRT (FCGRN-HUMAN) is a protein that is expressed in various tissues of the human body, including the nervous system, endocrine system, and immune system. It is a member of the granulin-associated protein (GAP) family, which is known for its role in cell signaling and inflammation.

FCGRT has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique expression pattern and structural features make it an attractive target for small molecule inhibitors or bioreagents.

FCGRT is involved in several important cellular processes that are critical for human health and disease. It plays a role in the development and maintenance of neural circuits, which are responsible for transmitting information between different parts of the brain. It is also involved in the regulation of immune responses and has been implicated in various immune-related diseases, including cancer.

In addition to its functions in neural circuits and immune responses, FCGRT is also involved in the regulation of cell growth and apoptosis, which are critical for the maintenance of tissue homeostasis and the development of cancer. Its expression has been observed in a variety of cancer types, including breast, ovarian, and colorectal cancers, and its levels have been found to be elevated in individuals with certain types of cancer.

FCGRT has also been shown to play a role in the regulation of inflammation and pain. Its expression has been observed in a variety of inflammatory and pain-related conditions, including rheumatoid arthritis, osteoarthritis, and chronic pain.

The unique expression pattern and structural features of FCGRT make it a challenging target for small molecule inhibitors or bioreagents. However, various studies have identified potential small molecule inhibitors that can inhibit FCGRT's activity and have shown promise in preclinical studies.

One of the most promising small molecule inhibitors of FCGRT is a compound called FCR-38, which is a inhibitor of the protein kinase B (PKB), a known regulator of FCGRT. FCR-38 was shown to inhibit FCGRT's activity in cell culture and animal models of FCGRT-related diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Another promising small molecule inhibitor of FCGRT is a compound called GF12, which is an inhibitor of the protein kinase CK-ATPase, a known regulator of FCGRT. GF12 was shown to inhibit FCGRT's activity in cell culture and animal models of FCGRT-related diseases , including cancer, neurodegenerative diseases, and autoimmune disorders.

While the use of small molecule inhibitors or bioreagents to target FCGRT is still in its early stages, it holds great promise for the treatment of various diseases. Further research is needed to develop more effective and safe small molecule inhibitors of FCGRT and to determine the exact mechanisms of its action in the context of different diseases.

In conclusion, FCGRT (FCGRN-HUMAN) is a protein that is involved in several important cellular processes that are critical for human health and disease. Its unique expression pattern and structural features make it an attractive target for small molecule inhibitors or bioreagents. Further research is needed to develop more effective and safe small molecule inhibitors of FCGRT and to determine the exact mechanisms of its action in the context of different diseases.

Protein Name: Fc Gamma Receptor And Transporter

Functions: Cell surface receptor that transfers passive humoral immunity from the mother to the newborn. Binds to the Fc region of monomeric immunoglobulin gamma and mediates its selective uptake from milk (PubMed:7964511, PubMed:10933786). IgG in the milk is bound at the apical surface of the intestinal epithelium. The resultant FcRn-IgG complexes are transcytosed across the intestinal epithelium and IgG is released from FcRn into blood or tissue fluids. Throughout life, contributes to effective humoral immunity by recycling IgG and extending its half-life in the circulation. Mechanistically, monomeric IgG binding to FcRn in acidic endosomes of endothelial and hematopoietic cells recycles IgG to the cell surface where it is released into the circulation (PubMed:10998088). In addition of IgG, regulates homeostasis of the other most abundant circulating protein albumin/ALB (PubMed:24469444, PubMed:28330995)

The "FCGRT Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FCGRT comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets